A Phase 2, Open-Label Study of Loncastuximab Tesirine in Combination with Rituximab (Lonca-R) in Previously Untreated Unfit/Frail Patients with Diffuse Large B-Cell Lymphoma (DLBCL) (LOTIS-9)

被引：2
|
作者：
Westin, Jason [1 ]
Burke, John M. [2 ]
Chapman, Andrew E. [3 ]
Kilavuz, Turk [4 ]
Xu, Cindy [4 ]
Schmuely, Yochi [4 ]
Stanford, Brad Lane [4 ]
Beedle, Emily [4 ]
Radford, John [5 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX USA
[2] Rocky Mt Canc Ctr, US Oncol Hematol Res Program, Aurora, CO USA
[3] Sidney Kimmel Canc Ctr Jefferson Hlth, Philadelphia, PA USA
[4] ADC Therapeut Amer Inc, Murray Hill, NJ USA
[5] Univ Manchester & Christie NHS Fdn Trust, NIHR Clin Res Facil, Manchester Acad Hlth Sci Ctr, Manchester, Lancs, England
来源：
BLOOD | 2022年 / 140卷
关键词：
D O I：
10.1182/blood-2022-162870
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：6638 / 6639
页数：2
相关论文
共 50 条
  • [1] A Phase 2, Open-Label Study of Loncastuximab Tesirine in Combination With Rituximab (Lonca-R) in Previously Untreated Unfit/Frail Patients With Diffuse Large B-Cell Lymphoma (LOTIS-9)
    Westin, Jason
    Burke, John M.
    Chapman, Andrew E.
    Kilavuz, Turk
    Xu, Cindy
    Shmuely, Yochi
    Radford, John
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S368 - S368
  • [2] Phase 3 randomized study of loncastuximab tesirine in combination with rituximab (Lonca-R) versus immunochemotherapy in patients with R/R DLBCL (LOTIS-5).
    Hamadani, Mehdi
    Linhares, Yuliya
    Gandhi, Mitul
    Chung, Michael
    Adamis, Helena
    Ungar, David
    Carlo-Stella, Carmelo
    Kingsley, Ed
    Depaus, Julien
    Snauwaert, Sylvia
    Kwiatek, Michal
    Lopez-Jimenez, Javier
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [3] LOTIS-5, an Ongoing, Phase 3, Randomized Study of Loncastuximab Tesirine With Rituximab (Lonca-R) Versus Immunochemotherapy in Patients With R/R DLBCL
    Kwiatek, Michal T.
    Carlo-Stella, Carmelo
    Urban, Andrzej
    Niewiarowski, Andrew
    Wang, Luqiang
    Laughlin, Mary
    Hamadani, Mehdi
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S473 - S474
  • [4] LOTIS-5: An ongoing, phase 3, randomized study of loncastuximab tesirine with rituximab (Lonca-R) versus immunochemotherapy in patients with R/R DLBCL.
    Kwiatek, Michal
    Carlo-Stella, Carmelo
    Urban, Andrzej
    Niewiarowski, Andrew
    Wang, Luqiang
    Hamadani, Mehdi
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [5] Phase 3 randomized study of loncastuximab tesirine plus rituximab versus immunochemotherapy in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): LOTIS-5.
    Hamadani, Mehdi
    Linhares, Yuliya
    Gandhi, Mitul
    Chung, Michael
    Adamis, Helena
    Ungar, David
    Carlo-Stella, Carmelo
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [6] Loncastuximab tesirine in previously treated diffuse large B-cell lymphoma: A plain language summary of the LOTIS-2 study
    Hamadani, Mehdi
    Caimi, Paolo F.
    Hess, Brian
    Radford, John
    Solh, Melhem
    Zinzani, Pier Luigi
    Wang, Luqiang
    Xu, Zhiying Cindy
    Carlo-Stella, Carmelo
    FUTURE ONCOLOGY, 2025, 21 (03) : 261 - 270
  • [7] Initial Safety Run-In Results of the Phase 3 LOTIS-5 Trial: Novel Combination of Loncastuximab Tesirine With Rituximab (Lonca-R) Versus Immunochemotherapy in Patients With R/R DLBCL
    Kingsley, Edwin
    Grosicki, Sebastian
    Kwiatek, Michal
    Salar, Antonio
    Snauwaert, Sylvia
    Wang, Ying
    Adamis, Helena
    Wang, Luqiang
    Depaus, Julien
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S372 - S372
  • [8] Updated Results of the Safety Run-In of the Phase 3 LOTIS-5 Trial: Novel Combination of Loncastuximab Tesirine With Rituximab (Lonca-R) Versus Immunochemotherapy in Patients With R/R DLBCL
    Kwiatek, Michal
    Grosicki, Sebastian
    Lopez Jimenez, Javier
    Pinzon Marino, Sergio Felipe
    Snauwaert, Sylvia
    Kingsley, Edwin
    Zacchetti, Giovanna
    Wang, Ying
    Wang, Luqiang
    Depaus, Julien
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S439 - S440
  • [9] Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial
    Caimi, Paolo F.
    Ai, Weiyun
    Alderuccio, Juan Pablo
    Ardeshna, Kirit M.
    Hamadani, Mehdi
    Hess, Brian
    Kahl, Brad S.
    Radford, John
    Solh, Melhem
    Stathis, Anastasios
    Zinzani, Pier Luigi
    Havenith, Karin
    Feingold, Jay
    He, Shui
    Qin, Yajuan
    Ungar, David
    Zhang, Xiaoyan
    Carlo-Stella, Carmelo
    LANCET ONCOLOGY, 2021, 22 (06): : 790 - 800
  • [10] LOTIS-2 Follow-Up Analysis: Updated Results from a Phase 2 Study of Loncastuximab Tesirine (Lonca) in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
    Kahl, Brad S.
    Hamadani, Mehdi
    Caimi, Paolo F.
    Carlo-Stella, Carmelo
    Ai, Weiyun
    Alderuccio, Juan Pablo
    Ardeshna, Kirit M.
    Hess, Brian
    Radford, John
    Solh, Melhem
    Stathis, Anastasios
    Feingold, Jay
    Ungar, David
    Qin, Yajuan
    He, Shui
    Zinzani, Pier Luigi
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S377 - S378
12345